Quality of Life of Cancer Patients under Adjuvant Mistletoe Treatment Results of a prospective, non-randomized, controlled, open study (post-marketing surveillance) with Iscador (R) M

被引:6
|
作者
Toelg, Michael [1 ]
Antonu, Herbert
Reiss, Bettina [1 ]
Ramos, Mac H. [2 ]
机构
[1] Mediveritas, Zweibruckenstr 15, DE-8033 Munich, Germany
[2] Weleda AG, CH-4144 Arlesheim, Switzerland
来源
关键词
prospective study; gynaecological cancer; mistletoe; chemotherapy; adverse events; quality of life; Iscador;
D O I
10.1159/000281947
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Mistletoe extracts (Viscum album L.) are applied in anthroposophic medicine in addition to conventional oncologic therapy, with the intention of reducing adverse events of chemotherapy and thereby improving the patients' qualitiy of life. Aim of the study: Documentation of the efficacy and tolerability of the anthroposophical mistletoe preparation Iscador (R) M in the treatment of patients with gynaecological cancer during chemotherapy, especially regarding the quality of life. Design: Prospective, controlled post-marketing surveillance. Methods: 36 female patients received a therapy with Iscador (R) in addition to the chemotherapeutical treatment, 37 female patients of the control group received exclusively a conventional therapy. The period of observation covered 6 months. Results: In comparison to the controlpatients the Iscador (R) patients showed better blood parameters and less physical and psychical impairment usually associated with chemotherapy. Conclusion: In summary, more patients of the Iscador (R) group experienced an amelioration or a stabilisation of their general condition and good tolerance of the mistletoe preparation.
引用
收藏
页码:294 / 299
页数:6
相关论文
共 46 条
  • [31] Effect of goserelin on the preservation of ovarian reserve function during (neo)adjuvant chemotherapy for young breast cancer patients: a prospective, non-randomized, open-label, cohort study (Interim analysis of proof study) (NCT02430103)
    Wang, S. Y.
    Wang, S.
    Pei, L.
    BREAST, 2019, 44 : S130 - S130
  • [32] Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
    Kenmotsu, Hirotsugu
    Sakai, Fumikazu
    Kato, Terufumi
    Kusumoto, Masahiko
    Baba, Tomohisa
    Kuwano, Kazuyoshi
    Gemma, Akihiko
    Nakagawa, Kazuhiko
    Nakanishi, Yoichi
    Yamamoto, Nobuyuki
    Ito, Yoshihiko
    Tahara, Yasuhiro
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE)
    Barlesi, F.
    Mercier, O.
    Lowczak, A.
    Mandziuk, S.
    Kuzdzal, J.
    Koutras, A.
    Dasgupta, A.
    Leyco, A. J.
    Andre, P.
    Mager, R.
    Fraenkel, P. G.
    Paturel, C. L.
    Chammard, A. Boyer
    ANNALS OF ONCOLOGY, 2023, 34 : S744 - S744
  • [34] In Metastatic Non-small cell Lung Cancer Platinum-Based Treated Patients, Herbal Treatment Improves the Quality of Life. A Prospective Randomized Controlled Clinical Trial
    Guo, Huiru
    Liu, Jia X.
    Li, Hegen
    Baak, Jan P. A.
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [35] Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer final - results from the prospective German TLK cohort study
    von Verschuer, Ulla
    Schnell, Roland
    Tessen, Hans Werner
    Eggert, Jochen
    Binninger, Adrian
    Spring, Lisa
    Jaenicke, Martina
    Marschner, Norbert
    LUNG CANCER, 2017, 112 : 216 - 224
  • [36] Quality of life under and efficacy of NEPA as CINV prophylaxis in patients with gastrointestinal cancer receiving highly or moderately emetogenic chemotherapy -Results of a German prospective non-interventional study
    Karthaus, M.
    Oskay-Oezcelik, G.
    Zahn, M. -O
    Haas, S.
    Kuhn, T.
    Schilling, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 213 - 213
  • [37] PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY TO EVALUATE QUALITY OF LIFE IN CHINESE POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE EARLY BREAST CANCER PATIENTS DURING TREATMENT WITH ADJUVANT AROMATASE INHIBITORS
    Cao, A.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Open Label Non-Randomized Phase II Study Exploring "Chemo-Free" Treatment Association with Idelalisib plus Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase
    Tomowiak, Cecile
    Desseaux, Kristell
    Poulain, Stephanie
    Herbaux, Charles
    Perrot, Aurore
    Mahe, Beatrice
    Morel, Pierre
    Tournilhac, Olivier
    Lepretre, Stephane
    Aurran, Therese
    Villemagne, Bruno
    Casasnovas, Olivier
    Nollet, Delphine
    Dreyfus, Brigitte
    Chevret, Sylvie
    Leblond, Veronique
    BLOOD, 2019, 134
  • [39] PROSPECTIVE, SINGLE-ARM, POST-MARKETING CLINICAL STUDY OF PEMETREXED (PEM) AND CARBOPLATIN COMBINATION FOLLOWED BY MAINTENANCE PEM IN CHEMO-NAiVE JAPANESE PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): 24 MONTH FOLLOW-UP OS RESULTS
    Hotta, K.
    Kiura, K.
    Kubota, K.
    Yoshizawa, H.
    Enatsu, S.
    Sekiguchi, R.
    Nakagawa, K.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 397 - 397
  • [40] Efficacy of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.
    Laktionov, Konstantin K.
    Arzumanyan, Alla L.
    Bolotina, Larisa
    Breder, Valeriy Vladimirovich
    Buevich, Natalia N.
    Danilova, Anastasia
    Filippova, Elena A.
    Kornietskaya, Anna
    Kramchaninov, Mikhail M.
    Kushniruk, Eugenia K.
    Latipova, Dilorom H.
    Moiseenko, Fedor Vladimirovich
    Nikitina, Tatiana P.
    Orlov, Sergey V.
    Orlova, Rashida
    Protsenko, Svetlana A.
    Sarantseva, Ksenia A.
    Stroyakovskiy, Daniil L.
    Zinkovskaya, Anna V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)